The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of the clinical features, treatment patterns, and tumor mutations of patients with intrahepatic (ICC) and extrahepatic (ECC) cholangiocarcinoma.
 
Leon Pappas
No Relationships to Disclose
 
Stephanie Reyes
No Relationships to Disclose
 
Aishwarya Lanka
No Relationships to Disclose
 
Rachna T. Shroff
Consulting or Advisory Role - Agios; Agios; Agios; Agios; Clovis Oncology; Clovis Oncology; Clovis Oncology; Clovis Oncology; Debiopharm Group; Debiopharm Group; Debiopharm Group; Debiopharm Group; Exelixis; Exelixis; Exelixis; Exelixis; Merck; Merck; Merck; Merck; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Seagen; Seagen; Seagen; Seagen
Research Funding - Agios; Agios; Agios; Agios; Exelixis; Exelixis; Exelixis; Exelixis; Halozyme; Halozyme; Halozyme; Halozyme; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Tri Minh Le
No Relationships to Disclose
 
Osama E. Rahma
Employment - Outcomes4me; Outcomes4me; Outcomes4me; Outcomes4me
Leadership - Outcomes4me; Outcomes4me; Outcomes4me; Outcomes4me
Honoraria - Alaunus Global; Alaunus Global; Alaunus Global; Alaunus Global; Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; Leerink; Leerink; Leerink; Leerink; Merck; Merck; Merck; Merck; MI Bioresearch; MI Bioresearch; MI Bioresearch; MI Bioresearch; PRMA Consulting; PRMA Consulting; PRMA Consulting; PRMA Consulting
Consulting or Advisory Role - Alcimed; Alcimed; Alcimed; Alcimed; Celgene; Celgene; Celgene; Celgene; Defined Health; Defined Health; Defined Health; Defined Health; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Five Prime Therapeutics; Genentech; Genentech; Genentech; Genentech; Gfk; Gfk; Gfk; Gfk; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Imvax; Imvax; Imvax; Imvax; Leerink; Leerink; Leerink; Leerink; Leerink; Leerink; Leerink; Leerink; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; Maverick Therapeutics; Merck; Merck; Merck; Merck; PureTech; PureTech; PureTech; PureTech; Putnam Associates; Putnam Associates; Putnam Associates; Putnam Associates
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Amgen (Inst); Merck; Merck; Merck; Merck
Patents, Royalties, Other Intellectual Property - PD-1/PD-L1 (Inst); PD-1/PD-L1 (Inst); PD-1/PD-L1 (Inst); PD-1/PD-L1 (Inst); Pending patent (DFCI 2386.010) (Inst); Pending patent (DFCI 2386.010) (Inst); Pending patent (DFCI 2386.010) (Inst); Pending patent (DFCI 2386.010) (Inst)
Travel, Accommodations, Expenses - Clinical Care Options; Clinical Care Options; Clinical Care Options; Clinical Care Options; Genentech; Genentech; Genentech; Genentech; Merck; Merck; Merck; Merck; PRMA Consulting; PRMA Consulting; PRMA Consulting; PRMA Consulting; PureTech; PureTech; PureTech; PureTech
 
Andrea Grace Bocobo
No Relationships to Disclose
 
Mitesh J. Borad
Stock and Other Ownership Interests - AVEO; AVEO; AVEO; AVEO; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline
Consulting or Advisory Role - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); ArQule (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); Fujifilm (Inst); G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; G1 Therapeutics; Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Inspyr Therapeutics; Inspyr Therapeutics; Inspyr Therapeutics; Inspyr Therapeutics; Insys Therapeutics (Inst); Insys Therapeutics (Inst); Insys Therapeutics (Inst); Insys Therapeutics (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Pieris Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TD2; TD2; TD2; TD2
Research Funding - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); ARIAD (Inst); ARIAD (Inst); ARIAD (Inst); ARIAD (Inst); BiolineRx (Inst); BiolineRx (Inst); BiolineRx (Inst); BiolineRx (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Dicerna (Inst); Dicerna (Inst); Dicerna (Inst); Dicerna (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); Halozyme (Inst); ImClone Systems (Inst); ImClone Systems (Inst); ImClone Systems (Inst); ImClone Systems (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Isis Pharmaceuticals (Inst); Isis Pharmaceuticals (Inst); Isis Pharmaceuticals (Inst); Isis Pharmaceuticals (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); miRNA Therapeutics (Inst); miRNA Therapeutics (Inst); miRNA Therapeutics (Inst); miRNA Therapeutics (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Senhwa Biosciences (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sillajen (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Threshold Pharmaceuticals (Inst); Threshold Pharmaceuticals (Inst); Threshold Pharmaceuticals (Inst); Threshold Pharmaceuticals (Inst); Toray Industries (Inst); Toray Industries (Inst); Toray Industries (Inst); Toray Industries (Inst)
Travel, Accommodations, Expenses - ArQule; ArQule; ArQule; ArQule; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Celgene; Celgene; Celgene; Celgene
 
Thomas DeLeon
No Relationships to Disclose
 
Kabir Mody
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Celgene; Celgene; Celgene; Celgene; Eisai; Eisai; Eisai; Eisai; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Merrimack; Merrimack; Merrimack; Merrimack; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics; Vicus Therapeutics
Research Funding - Agios; Agios; Agios; Agios; ARIAD; ARIAD; ARIAD; ARIAD; ArQule; ArQule; ArQule; ArQule; FibroGen; FibroGen; FibroGen; FibroGen; MedImmune; MedImmune; MedImmune; MedImmune; Senhwa Biosciences; Senhwa Biosciences; Senhwa Biosciences; Senhwa Biosciences; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; TRACON Pharma; TRACON Pharma; TRACON Pharma; TRACON Pharma
 
Marc Thomas Roth
No Relationships to Disclose
 
Mary Linton Bounetheau Peters
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbott Laboratories (I); Abbott Laboratories (I); Abbott Laboratories (I); Amgen (I); Amgen (I); Amgen (I); Amgen (I); Johnson & Johnson (I); Johnson & Johnson (I); Johnson & Johnson (I); Johnson & Johnson (I); Lilly; Lilly; Lilly; Lilly; Lilly (I); Lilly (I); Lilly (I); Lilly (I); Medtronic; Medtronic; Medtronic; Medtronic; Medtronic (I); Medtronic (I); Medtronic (I); Medtronic (I); Merck; Merck; Merck; Merck; Pfizer (I); Pfizer (I); Pfizer (I); Pfizer (I); Procter & Gamble; Procter & Gamble; Procter & Gamble; Procter & Gamble
Honoraria - Bayer; Bayer; Bayer; Bayer; Exelixis; Exelixis; Exelixis; Exelixis
Consulting or Advisory Role - Agios; Agios; Agios; Agios
Research Funding - Ambry Genetics (Inst); Ambry Genetics (Inst); Ambry Genetics (Inst); Ambry Genetics (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); Berg Pharma (Inst); Berg Pharma (Inst); Berg Pharma (Inst); Berg Pharma (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Exelixis; Exelixis; Exelixis; Exelixis; Halozyme; Halozyme; Halozyme; Halozyme
 
Laura Williams Goff
Consulting or Advisory Role - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Competitive Drug Development International; Competitive Drug Development International; Competitive Drug Development International; Competitive Drug Development International; Eisai; Eisai; Eisai; Eisai; Lilly; Lilly; Lilly; Lilly; Newlink Genetics; Newlink Genetics; Newlink Genetics; Newlink Genetics; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics
Research Funding - Agios; Agios; Agios; Agios; ArQule; ArQule; ArQule; ArQule; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; ASLAN Pharmaceuticals; Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; Basilea; Basilea; Basilea; Basilea; BeiGene; BeiGene; BeiGene; BeiGene; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; H3 Biomedicine; H3 Biomedicine; H3 Biomedicine; H3 Biomedicine; Incyte; Incyte; Incyte; Incyte; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Leap Therapeutics; Lilly; Lilly; Lilly; Lilly; Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Onyx; Onyx; Onyx; Onyx; Pfizer; Pfizer; Pfizer; Pfizer; Sun Pharma; Sun Pharma; Sun Pharma; Sun Pharma
 
Kylie Boyhen
Stock and Other Ownership Interests - Editas Medicine; Editas Medicine; Editas Medicine; Editas Medicine
 
Christine VanCott
No Relationships to Disclose
 
Nora Horick
No Relationships to Disclose
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)
 
Milind M. Javle
Consulting or Advisory Role - incyte; incyte; incyte; incyte; Mundipharma; Mundipharma; Mundipharma; Mundipharma; oncosil; oncosil; oncosil; oncosil; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics
Other Relationship - Bayer; Bayer; Bayer; Bayer; BeiGene; BeiGene; BeiGene; BeiGene; Incyte; Incyte; Incyte; Incyte; Merck; Merck; Merck; Merck; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Novartis; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; Pieris Pharmaceuticals; QED Therapeutics; QED Therapeutics; QED Therapeutics; QED Therapeutics; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Rafael Pharmaceuticals; Seagen; Seagen; Seagen; Seagen
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Target Pharmasolutions; Target Pharmasolutions; Target Pharmasolutions; Target Pharmasolutions; Target Pharmasolutions (Inst); Target Pharmasolutions (Inst); Target Pharmasolutions (Inst); Target Pharmasolutions (Inst)
Research Funding - Adaptimmune (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Adaptimmune (Inst); Agios (Inst); Agios (Inst); Agios (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); Celgene (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); EMD Serono (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Exelixis (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Regeneron (Inst); Regeneron (Inst); Regeneron (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tekmira (Inst); Tekmira (Inst); Tekmira (Inst); Tekmira (Inst)
 
Lipika Goyal
No Relationships to Disclose